Table 1.
Demographic and baseline characteristics
| Characteristic | Treatment groupa | ||||
|---|---|---|---|---|---|
| Group A | Group B | Group C | Group D | Total | |
| N = 323 | N = 65 | N = 106 | N = 21 | N = 515 | |
| Age, years | |||||
| Mean (SD) | 45.6 (9.3) | 44.2 (9.5) | 44.8 (8.2) | 42.5 (10.0) | 45.2 (9.2) |
| Range | 20–64 | 24–60 | 26–63 | 23–57 | 20–64 |
| Sex, n (%) | |||||
| Male | 43 (13.3) | 9 (13.8) | 13 (12.3) | 3 (14.3) | 68 (13.2) |
| Female | 280 (86.7) | 56 (86.2) | 93 (87.7) | 18 (85.7) | 447 (86.8) |
| Race, n (%) | |||||
| Asian | 323 (100) | 65 (100) | 106 (100) | 21 (100) | 515 (100) |
| Appearance of glabellar lines at maximum frown, measured by ILA, n (%) | |||||
| Moderate (Grade 2) | 139 (43.0) | 29 (44.6) | 46 (43.4) | 8 (38.1) | 222 (43.1) |
| Severe (Grade 3) | 184 (57.0) | 36 (55.4) | 60 (56.6) | 13 (61.9) | 293 (56.9) |
| Botulinum toxin status, n (%) | |||||
| Naïve | 295 (91.3) | 61 (93.8) | 100 (94.3) | 19 (90.5) | 475 (92.2) |
| Non-naïveb | 28 (8.7) | 4 (6.2) | 6 (5.7) | 2 (9.5) | 40 (7.8) |
Data are shown from the mITT population. aTreatment group in cycle 1. bPatients who were non-naïve to botulinum toxin had received their most recent BoNT-A treatment more than 1 year prior to screening, in any muscle of the face. Group A = patients who received aboBoNT-A 50 U; Group B = patients who received matching aboBoNT-A placebo; Group C = patients who received onaBoNT-A 20 U; Group D = patients who received matching onaBoNT-A placebo; AboBoNT-A = abobotulinumtoxinA; ILA = investigator’s live assessment; mITT = modified intent-to-treat; N = total number of patients; n = number of patients with an assessment; onaBoNT-A = onabotulinumtoxinA; SD = standard deviation; U = unit